Paul Matteis
Stock Analyst at Stifel
(2.99)
# 1,543
Out of 5,090 analysts
122
Total ratings
45.68%
Success rate
0.13%
Average return
Main Sectors:
Stocks Rated by Paul Matteis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MPLT MapLight Therapeutics | Initiates: Buy | $28 | $18.49 | +51.43% | 1 | Nov 21, 2025 | |
| NMRA Neumora Therapeutics | Maintains: Hold | $2 → $3 | $2.22 | +35.14% | 3 | Nov 17, 2025 | |
| BMRN BioMarin Pharmaceutical | Downgrades: Hold | $73 → $61 | $53.40 | +14.23% | 11 | Nov 6, 2025 | |
| BIIB Biogen | Upgrades: Buy | $144 → $202 | $181.30 | +11.42% | 7 | Nov 6, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Hold | $455 → $445 | $455.48 | -2.30% | 20 | Nov 4, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $174 → $183 | $155.51 | +17.68% | 10 | Oct 29, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $441 → $495 | $458.12 | +8.05% | 15 | Oct 6, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Hold | $43 → $67 | $81.68 | -17.97% | 6 | Oct 6, 2025 | |
| LBRX LB Pharmaceuticals | Initiates: Buy | $27 | $19.50 | +38.46% | 1 | Oct 6, 2025 | |
| PEPG PepGen | Maintains: Buy | $9 → $12 | $5.44 | +120.59% | 3 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $65 | $21.33 | +204.74% | 2 | Sep 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $66 → $36 | $20.28 | +77.51% | 4 | Jul 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $78 → $94 | $104.60 | -10.13% | 2 | May 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $32 | $40.29 | -20.58% | 1 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $32 | $14.89 | +114.91% | 2 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $11 | $5.82 | +89.00% | 1 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $4 | $1.23 | +226.53% | 4 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $10 | $13.43 | -25.54% | 3 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $44 → $60 | $20.28 | +195.86% | 2 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $25 → $36 | $29.52 | +21.95% | 8 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $29.50 | +18.64% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $26 → $21 | $27.44 | -23.47% | 5 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $29 | $11.04 | +162.68% | 1 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $9.35 | +113.90% | 1 | Nov 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $4.33 | +177.14% | 1 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $360 → $50 | $3.85 | +1,198.70% | 2 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $54 → $32 | $16.43 | +94.77% | 1 | Jun 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $1.86 | +1,351.61% | 1 | Jul 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $14 | $21.34 | -34.40% | 1 | Mar 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $53 → $64 | $7.49 | +754.47% | 1 | Feb 21, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $340 | $220.36 | +54.29% | 1 | Dec 21, 2016 |
MapLight Therapeutics
Nov 21, 2025
Initiates: Buy
Price Target: $28
Current: $18.49
Upside: +51.43%
Neumora Therapeutics
Nov 17, 2025
Maintains: Hold
Price Target: $2 → $3
Current: $2.22
Upside: +35.14%
BioMarin Pharmaceutical
Nov 6, 2025
Downgrades: Hold
Price Target: $73 → $61
Current: $53.40
Upside: +14.23%
Biogen
Nov 6, 2025
Upgrades: Buy
Price Target: $144 → $202
Current: $181.30
Upside: +11.42%
Vertex Pharmaceuticals
Nov 4, 2025
Maintains: Hold
Price Target: $455 → $445
Current: $455.48
Upside: -2.30%
Neurocrine Biosciences
Oct 29, 2025
Maintains: Buy
Price Target: $174 → $183
Current: $155.51
Upside: +17.68%
Alnylam Pharmaceuticals
Oct 6, 2025
Maintains: Buy
Price Target: $441 → $495
Current: $458.12
Upside: +8.05%
Ionis Pharmaceuticals
Oct 6, 2025
Maintains: Hold
Price Target: $43 → $67
Current: $81.68
Upside: -17.97%
LB Pharmaceuticals
Oct 6, 2025
Initiates: Buy
Price Target: $27
Current: $19.50
Upside: +38.46%
PepGen
Sep 25, 2025
Maintains: Buy
Price Target: $9 → $12
Current: $5.44
Upside: +120.59%
Sep 24, 2025
Maintains: Buy
Price Target: $30 → $65
Current: $21.33
Upside: +204.74%
Jul 31, 2025
Maintains: Buy
Price Target: $66 → $36
Current: $20.28
Upside: +77.51%
May 29, 2025
Maintains: Buy
Price Target: $78 → $94
Current: $104.60
Upside: -10.13%
Mar 4, 2025
Initiates: Buy
Price Target: $32
Current: $40.29
Upside: -20.58%
Feb 27, 2025
Maintains: Buy
Price Target: $18 → $32
Current: $14.89
Upside: +114.91%
Feb 27, 2025
Initiates: Buy
Price Target: $11
Current: $5.82
Upside: +89.00%
Dec 16, 2024
Downgrades: Hold
Price Target: $4
Current: $1.23
Upside: +226.53%
Nov 13, 2024
Maintains: Buy
Price Target: $32 → $10
Current: $13.43
Upside: -25.54%
Nov 12, 2024
Maintains: Buy
Price Target: $44 → $60
Current: $20.28
Upside: +195.86%
Nov 5, 2024
Upgrades: Buy
Price Target: $25 → $36
Current: $29.52
Upside: +21.95%
Jul 2, 2024
Initiates: Buy
Price Target: $35
Current: $29.50
Upside: +18.64%
May 9, 2024
Maintains: Hold
Price Target: $26 → $21
Current: $27.44
Upside: -23.47%
Apr 30, 2024
Initiates: Buy
Price Target: $29
Current: $11.04
Upside: +162.68%
Nov 28, 2023
Initiates: Buy
Price Target: $20
Current: $9.35
Upside: +113.90%
Nov 14, 2023
Initiates: Buy
Price Target: $12
Current: $4.33
Upside: +177.14%
Jun 23, 2022
Downgrades: Hold
Price Target: $360 → $50
Current: $3.85
Upside: +1,198.70%
Jun 8, 2022
Maintains: Buy
Price Target: $54 → $32
Current: $16.43
Upside: +94.77%
Jul 26, 2021
Initiates: Buy
Price Target: $27
Current: $1.86
Upside: +1,351.61%
Mar 12, 2020
Initiates: Buy
Price Target: $14
Current: $21.34
Upside: -34.40%
Feb 21, 2018
Maintains: Outperform
Price Target: $53 → $64
Current: $7.49
Upside: +754.47%
Dec 21, 2016
Initiates: Outperform
Price Target: $340
Current: $220.36
Upside: +54.29%